A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission.

Summary, in English

Treatment with tumour necrosis factor (TNF) blockers, once started as therapy for rheumatoid arthritis (RA), is usually continued indefinitely. The aim of this trial was to assess the possibility of discontinuing treatment with adalimumab (ADA) while maintaining remission in patients with RA with established disease in stable remission on combination therapy with ADA and methotrexate (MTX).

• Författare: Katerina Chatzidionysiou; Carl Turesson; Annika Teleman; Ann Knight; Elisabet Lindqvist; Per Larsson; Lars Cöster; Kristina Forslind; Ronald van Vollenhoven; Mikael Heimbürger
• Avdelning/ar: Internmedicin - epidemiologi; Reumatologi och molekylär skelettbiologi; Kliniska Vetenskaper, Helsingborg; EpiHealth: Epidemiology for Health
• Publiceringsår: 2016
• Språk: Engelska
• Sidor: 000133-000133
• Publikation/Tidskrift/Serie: RMD Open
• Volym: 2
• Issue: 1
• Länkar: http://www.ncbi.nlm.nih.gov/pubmed/26819752?dopt=Abstract; http://dx.doi.org/10.1136/rmdopen-2015-000133
• Dokumenttyp: Artikel i tidskrift
• Förlag: BMJ Publishing Group
• Ämne: Rheumatology and Autoimmunity
• Status: Published
• Forskningsgrupp: Internal Medicine - Epidemiology
• ISBN/ISSN/Övrigt: ISSN: 2056-5933